238 related articles for article (PubMed ID: 22031860)
21. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
23. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
[TBL] [Abstract][Full Text] [Related]
24. Proteolytic antibodies activate factor IX in patients with acquired hemophilia.
Wootla B; Christophe OD; Mahendra A; Dimitrov JD; Repessé Y; Ollivier V; Friboulet A; Borel-Derlon A; Levesque H; Borg JY; Andre S; Bayry J; Calvez T; Kaveri SV; Lacroix-Desmazes S
Blood; 2011 Feb; 117(7):2257-64. PubMed ID: 21131590
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for hemophilia: looking beyond factor expression.
Yamaguti-Hayakawa GG; Ozelo MC
Exp Biol Med (Maywood); 2022 Dec; 247(24):2223-2232. PubMed ID: 36691324
[TBL] [Abstract][Full Text] [Related]
27. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
29. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
[TBL] [Abstract][Full Text] [Related]
30. Viral vector-mediated gene therapy for hemophilia.
VandenDriessche T; Collen D; Chuah MK
Curr Gene Ther; 2001 Sep; 1(3):301-15. PubMed ID: 12109144
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
Margaritis P; Roy E; Aljamali MN; Downey HD; Giger U; Zhou S; Merricks E; Dillow A; Ezban M; Nichols TC; High KA
Blood; 2009 Apr; 113(16):3682-9. PubMed ID: 19109232
[TBL] [Abstract][Full Text] [Related]
32. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.
Siner JI; Samelson-Jones BJ; Crudele JM; French RA; Lee BJ; Zhou S; Merricks E; Raymer R; Nichols TC; Camire RM; Arruda VR
JCI Insight; 2016 Oct; 1(16):e89371. PubMed ID: 27734034
[TBL] [Abstract][Full Text] [Related]
33. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
34. [Molecular genetics of hemophilia A].
De Brasi CD; Slavutsky IR; Larripa IB
Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
[TBL] [Abstract][Full Text] [Related]
35. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.
Roth SD; Schüttrumpf J; Milanov P; Abriss D; Ungerer C; Quade-Lyssy P; Simpson JC; Pepperkok R; Seifried E; Tonn T
PLoS One; 2012; 7(9):e44505. PubMed ID: 22973456
[TBL] [Abstract][Full Text] [Related]
36. Coagulation factors with improved properties for hemophilia gene therapy.
Pipe SW
Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
[TBL] [Abstract][Full Text] [Related]
37. Preclinical animal models for hemophilia gene therapy: predictive value and limitations.
Rawle FE; Lillicrap D
Semin Thromb Hemost; 2004 Apr; 30(2):205-13. PubMed ID: 15118932
[TBL] [Abstract][Full Text] [Related]
38. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.
Lin CN; Kao CY; Miao CH; Hamaguchi N; Wu HL; Shi GY; Liu YL; High KA; Lin SW
J Thromb Haemost; 2010 Aug; 8(8):1773-83. PubMed ID: 20492477
[TBL] [Abstract][Full Text] [Related]
39. [Congenital hemophilia: a new treatment paradigm].
Shima M
Rinsho Ketsueki; 2019; 60(6):647-658. PubMed ID: 31281158
[TBL] [Abstract][Full Text] [Related]
40. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
Lu Q; Yang L; Manithody C; Wang X; Rezaie AR
Biochemistry; 2015 Jun; 54(24):3814-21. PubMed ID: 26023895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
